Antiviral potential of combinations of etiotropic antiherpetic agents including LAS-131, a novel terminase complex inhibitor, to affect the reproduction of herpes simplex virus type 1 (Orthoherpesviridae: Simplexvirus: Simplexvirus humanalpha1)
Open Access
- 28 February 2026
- journal article
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 71 (1) , 21-31
Abstract
Introduction. Herpes simplex virus type 1 (HSV-1) causes various diseases in humans that can lead to disability and death. Current treatments are effective and relatively safe. However, the high prevalence of HSV, the necessity for long-term therapy associated with the development of drug resistance in the virus (mainly in immunocompromised patients) and severe side effects of second-line drugs complicate treatment. Obviously, there is a necessity to develop therapeutic agents with a new mechanism of action and new ways of influencing herpes infection to improve the effectiveness of therapy. The combined use of drugs with different mechanisms of action is one such approach. The aim of the study is to evaluate the antiviral activity of combinations of LAS-131 ((3S)-4-[6-(purin-6-yl)aminohexanoyl]-3,4-dihydro-3-methyl-7,8-difluoro-2H-[1,4]-benzoxazine) with basic antiherpetic drugs and with two new compounds. Materials and methods. The effect of LAS-131 combinations against HSV-1 was studied by constructing an isobologram and calculating the fractional inhibitory concentration index. Results. LAS-131 selectively inhibits the reproduction of acyclovir-sensitive and -resistant HSV-1 variants (IC50 is 1.95 μg/mL, selectivity index is 63). Its target protein is the large subunit of the terminase complex (pUL15). When LAS-131 is used in combination with viral DNA polymerase inhibitors (acyclovir and related compounds) or with the minor-groove inhibitor 15Lys-bis-netropsin, a potentiating effect is observed, which allows decreasing the concentrations of the combined compounds by 4 times or more while maintaining antiviral activity. LAS-131 interacted additively with foscarnet, ribavirin, and α-interferon. Conclusion. Combinations of LAS-131 with known antiviral agents have been established, providing synergistic and additive effects of interaction against HSV-1.Keywords
This publication has 26 references indexed in Scilit:
- Update and latest advances in antiretroviral therapyTrends in Pharmacological Sciences, 2022
- Architecture of the herpesvirus genome-packaging complex and implications for DNA translocationProtein & Cell, 2020
- N‐[ω‐(Purin‐6‐yl)aminoalkanoyl] Derivatives of Chiral Heterocyclic Amines as Promising Anti‐Herpesvirus AgentsEuropean Journal of Organic Chemistry, 2019
- The human cytomegalovirus terminase complex as an antiviral target: a close-up viewFEMS Microbiology Reviews, 2018
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practiceJournal of Hepatology, 2016
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 2015
- Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2Journal of Antimicrobial Chemotherapy, 2015
- Complex of the herpes simplex virus type 1 origin binding protein UL9 with DNA as a platform for the design of a new type of antiviral drugsJournal of Biomolecular Structure and Dynamics, 2013
- Molecular genetic analysis of thymidine kinase of the herpes simplex virus type 1Molecular Biology, 2005
- Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase geneJournal of General Virology, 2000